The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Crizotinib in Anaplastic Large-Cell Lymphoma
Open accessAbstract
Crizotinib in Anaplastic Large-Cell LymphomaTo the Editor: Crizotinib, an inhibitor of the anaplastic lymphoma kinase (ALK) tyrosine kinase, is active in non-small-cell lung cancers that have ALK expression. 1 ALK is fused to several partner genes (mainly the gene encoding nucleophosmin) in the majority of anaplastic large-cell lymphomas (ALCLs).ALK tyrosine kinase activity represents the driver alteration in this disease. 2ALK-positive ALCLs are highly responsive to cytotoxic drugs.However, relapses occur and require salvage therapy.We treated two patients who had relapsed ALK-positive ALCL with crizotinib at a dose of 250 mg twice daily.No glucocorticoids or other drugs with antineoplastic activity were allowed.Patient 1, a 26-year-old woman, received seven cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP-15) and had a partial response at 1 month.She was subsequently treated with standard salvage combination chemotherapy regimens in an attempt to prepare for autologous bone marrow transplantation.However, relapse occurred within 2 to 3 weeks after each regimen.Pretreatment evaluation included fever (temperatures >38°C), cervical and inguinal adenopathy, and positive results on positron-emission tomographic (PET) and computed tomographic (CT) images of paraaortic and iliac nodes; bone marrow aspiration showed 3% of cells with ALK rearrangement.She had a score of 3 on the Eastern Cooperative Oncology Group (ECOG) performance scale (indicating confinement to bed or chair 50% or more of waking hours).After the initiation of crizotinib, Patient 1's fever disappeared within 48 hours; by day 7, all palpable adenopathy had resolved.PET and CT images and bone marrow aspiration performed at 28 days showed complete regression of previous
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Kwak, E. L., Bang, Y.-J., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S.-H. I., Dezube, B. J., Jänne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,446
The anaplastic lymphoma kinase in the pathogenesis of cancer
Chiarle, R., Voena, C., Ambrogio, C., Piva, R., & Inghirami, G. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2291 · Cited by 882
Cited by
Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer
Shaw, A. T., Kim, D.-W., Nakagawa, K., Seto, T., Crinó, L., Ahn, M.-J., De Pas, T., Besse, B., Solomon, B. J., Blackhall, F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214886 · Cited by 3,381
Cui, J. J., Tran-Dubé, M., Shen, H., Nambu, M., Kung, P.-P., Pairish, M., Jia, L., Meng, J., Funk, L., Botrous, I., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm2007613 · Cited by 932
TRKing Down an Old Oncogene in a New Era of Targeted Therapy
Vaishnavi, A., Le, A. T., & Doebele, R. C. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0765 · Cited by 642
A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase Inhibitors
Sasaki, T., Koivunen, J., Ogino, A., Yanagita, M., Nikiforow, S., Zheng, W., Lathan, C., Marcoux, J. P., Du, J., Okuda, K., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1340 · Cited by 597
Crizotinib in Advanced, Chemoresistant Anaplastic Lymphoma Kinase–Positive Lymphoma Patients
Gambacorti Passerini, C., Farina, F., Stasia, A., Redaelli, S., Ceccon, M., Mologni, L., Messa, C., Guerra, L., Giudici, G., Sala, E., et al. (2014) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djt378 · Cited by 279
Self-citation
Metadata
- Authors
- Gambacorti-Passerini, C., Messa, C., & Pogliani, E. M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-02-24
- Volume
- 364
- Issue
- 8
- Pages
- 775-776
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1990487163
- Cited by
- 276
- References
- 2
- FWCI
- 24.41
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.